A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy.

Diabetes Care · 2010 · PMC2890365 · PMID 20413516

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significantno p-value reported

With respect to clinical characteristics, benfotiamine resulted in a borderline significant increase in plasma creatinine, but this was not accompanied by changes in creatinine clearance or cystatin C.

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.